BioNTech Investors Face Legal Challenge Following CureVac Acquisition

Investors in Mainz-based biotechnology firm BioNTech are navigating a complex landscape of strategic progress and fresh legal uncertainty. The company has successfully finalized its acquisition of rival CureVac, a move seen as strategically vital, only to be confronted with a new lawsuit from pharmaceutical giant Bayer. This juxtaposition marks a shift from resolving one patent dispute to potentially entering another, keeping the focus on legal risks surrounding mRNA technology.

The period of legal calm was brief. Confirmed this Wednesday, Bayer—specifically its Monsanto unit—has filed a lawsuit alleging the misuse of proprietary mRNA technology in the development of COVID-19 vaccines. The legal action targets not only BioNTech but Read more...